Prevalence, Risk Factors, Lung Function, and Associated Comorbidities of Adult Preserved Ratio Impaired Spirometry: A Meta-Analysis

Abstract

It is demonstrated that preserved ratio impaired spirometry (PRISm) is associated with chronic obstructive pulmonary disease development and mortality. However, comprehensive evidence on its prevalence, risk factors, lung function, and comorbidities is ambiguous. We searched for relevant studies from Medline, Web of Science, Embase, and Scopus up to March 26, 2024, and conducted a meta-analysis based on PRISMA 2020 to merge the results of eligible studies to reveal the prevalence, risk factors, lung function, and associated comorbidities in PRISm population. Thirty-two studies involving 1,196,856 participants were included. The prevalence of PRISm was 11% (95%CI: 10–13%), with decreased forced vital capacity (FVC) (L) (MD: −0.78, 95%CI: −0.90 to −0.66) and FVC% predicted (MD: −24.74, 95%CI: −26.33 to −23.16). Older age, high body mass index, current or ever smoking, and low education were positively associated with PRISm, while cardiovascular and endocrine comorbidities were common in patients with PRISm. The prevalence of PRISm is high in general population, with multiple risk factors, reduced lung function, and increased comorbidities. Therefore, clinicians should raise more concerns regarding this population to benefit them.

Keywords

preserved ratio impaired spirometry / prevalence / risk factor / comorbidities / meta-analysis

References

[1] T. Vos, A. D. Flaxman, M. Naghavi, et al., “Years Lived With Disability (YLDs) for 1160 Sequelae of 289 Diseases and Injuries 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010,” Lancet 380, no. 9859 (2012): 2163-2196.

[2] Prevalence and Attributable Health Burden of Chronic respiratory Diseases, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 2020; 8(6): 585-596.

[3] E. S. Wan, J. E. Hokanson, J. R. Murphy, et al., “Clinical and Radiographic Predictors of GOLD-unclassified Smokers in the COPDGene Study,” American Journal of Respiratory and Critical Care Medicine 184, no. 1 (2011): 57-63.

[4] E. S. Wan, P. J. Castaldi, M. H. Cho, et al., “Epidemiology, Genetics, and Subtyping of Preserved Ratio Impaired Spirometry (PRISm) in COPDGene,” Respiratory Research 15, no. 1 (2014): 89.

[5] A. Agustí, B. R. Celli, G. J. Criner, et al., “Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary,” European Respiratory Journal 61, no. 4 (2023).

[6] E. S. Wan, S. Fortis, E. A. Regan, et al., “Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study,” American Journal of Respiratory and Critical Care Medicine 198, no. 11 (2018): 1397-1405.

[7] M. S. Godfrey and M. D. Jankowich, “The Vital Capacity Is Vital: Epidemiology and Clinical Significance of the Restrictive Spirometry Pattern,” Chest 149, no. 1 (2016): 238-251.

[8] G. Li, M. D. Jankowich, L. Wu, et al., “Preserved Ratio Impaired Spirometry and Risks of Macrovascular, Microvascular Complications and Mortality among Individuals with Type 2 Diabetes,” Chest 164, no. 5 (2023): 1268-1280.

[9] S. Yang, G. Liao, and L. A. Tse, “Association of Preserved Ratio Impaired Spirometry With Mortality: A Systematic Review and Meta-analysis,” Eur Respir Rev 32, no. 170 (2023).

[10] S. R. A. Wijnant, E. De Roos, M. Kavousi, et al., “Trajectory and Mortality of Preserved Ratio Impaired Spirometry: The Rotterdam Study,” European Respiratory Journal 55, no. 1 (2020).

[11] K. Anami, S. Murata, H. Nakano, et al., “Physical Performance in Relation to Preserved Ratio Impaired Spirometry: A Cross-sectional Study of Community-dwelling Older Japanese Adults,” Scientific Reports 11, no. 1 (2021): 17411.

[12] T. Kaise, E. Sakihara, K. Tamaki, et al., “Prevalence and Characteristics of Individuals With Preserved Ratio Impaired Spirometry (PRISm) and/or Impaired Lung Function in Japan: The OCEAN Study,” Int J Chron Obstruct Pulmon Dis 16 (2021): 2665-2675.

[13] J. L. Marott, T. S. Ingebrigtsen, Y. Çolak, J. Vestbo, and P. Lange, “Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis,” American Journal of Respiratory and Critical Care Medicine 204, no. 8 (2021): 910-920.

[14] A. Schwartz, N. Arnold, B. Skinner, et al., “Preserved Ratio Impaired Spirometry in a Spirometry Database,” Respiratory Care 66, no. 1 (2021): 58-65.

[15] E. S. Wan, P. Balte, J. E. Schwartz, et al., “Association between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults,” Jama 326, no. 22 (2021): 2287-2298.

[16] D. H. Higbee, R. Granell, G. Davey Smith, and J. W. Dodd, “Prevalence, Risk Factors, and Clinical Implications of Preserved Ratio Impaired Spirometry: A UK Biobank Cohort Analysis,” Lancet Respir Med 10, no. 2 (2022): 149-157.

[17] R. Kaaks, E. Christodoulou, E. Motsch, et al., “Lung Function Impairment in the German Lung Cancer Screening Intervention Study (LUSI): Prevalence, Symptoms, and Associations With Lung Cancer Risk, Tumor Histology and all-cause Mortality,” Translational Lung Cancer Research 11, no. 9 (2022): 1896-1911.

[18] R. Kanetake, K. Takamatsu, K. Park, and A. Yokoyama, “Prevalence and Risk Factors for COPD in Subjects With Preserved Ratio Impaired Spirometry,” BMJ Open Respir Res 9, no. 1 (2022).

[19] J. Kim, C. H. Lee, H. Y. Lee, and H. Kim, “Association Between Comorbidities and Preserved Ratio Impaired Spirometry: Using the Korean National Health and Nutrition Examination Survey IV-VI,” Respiration 101, no. 1 (2022): 25-33.

[20] Y. Shiraishi, T. Shimada, N. Tanabe, et al., “The Prevalence and Physiological Impacts of Centrilobular and Paraseptal Emphysema on Computed Tomography in Smokers With Preserved Ratio Impaired Spirometry,” ERJ Open Res 8, no. 2 (2022).

[21] N. Tanabe, I. Masuda, Y. Shiraishi, et al., “Clinical Relevance of Multiple Confirmed Preserved Ratio Impaired Spirometry Cases in Adults,” Respir Investig 60, no. 6 (2022): 822-830.

[22] X. Tang, J. Lei, W. Li, et al., “The Relationship between BMI and Lung Function in Populations With Different Characteristics: A Cross-Sectional Study Based on the Enjoying Breathing Program in China,” Int J Chron Obstruct Pulmon Dis 17 (2022): 2677-2692.

[23] Y. Washio, S. Sakata, S. Fukuyama, et al., “Risks of Mortality and Airflow Limitation in Japanese Individuals With Preserved Ratio Impaired Spirometry,” American Journal of Respiratory and Critical Care Medicine 206, no. 5 (2022): 563-572.

[24] N. Zhao, F. Wu, J. Peng, et al., “Preserved Ratio Impaired Spirometry Is Associated With Small Airway Dysfunction and Reduced Total Lung Capacity,” Respiratory Research 23, no. 1 (2022): 298.

[25] C. Chen, S. Zhang, T. Yang, C. Wang, and G. Han, “Associations Between Environmental Heavy Metals Exposure and Preserved Ratio Impaired Spirometry in the U.S. adults,” Environmental Science and Pollution Research International 30, no. 49 (2023): 108274-108287.

[26] J. Fan, L. Fang, S. Cong, et al., “Potential Pre-COPD Indicators in Association With COPD Development and COPD Prediction Models in Chinese: A Prospective Cohort Study,” Lancet Reg Health West Pac 44 (2023): 100984.

[27] M. Kogo, S. Sato, S. Muro, et al., “Longitudinal Changes and Association of Respiratory Symptoms With Preserved Ratio Impaired Spirometry (PRISm): The Nagahama Study,” Ann Am Thorac Soc 20, no. 11 (2023): 1578-1586.

[28] S. Krishnan, W. C. Tan, R. Farias, et al., “Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease: A Canadian Cohort Study,” Chest 164, no. 3 (2023): 637-649.

[29] W. W. Labaki, T. Gu, S. Murray, et al., “Causes of and Clinical Features Associated With Death in Tobacco Cigarette Users by Lung Function Impairment,” American Journal of Respiratory and Critical Care Medicine 208, no. 4 (2023): 451-460.

[30] K. M. A. Magner, M. Cherian, G. A. Whitmore, et al., “Assessment of Preserved Ratio Impaired Spirometry Using Pre- and Post-Bronchodilator Spirometry in a Randomly Sampled Symptomatic Cohort,” American Journal of Respiratory and Critical Care Medicine 208, no. 10 (2023): 1129-1131.

[31] J. L. Marott, T. S. Ingebrigtsen, Y. Çolak, et al., “Impact of the Metabolic Syndrome on Cardiopulmonary Morbidity and Mortality in Individuals With Lung Function Impairment: A Prospective Cohort Study of the Danish General Population,” Lancet Reg Health Eur 35 (2023): 100759.

[32] S. Miura, H. Iwamoto, K. Omori, et al., “Preserved Ratio Impaired Spirometry With or Without Restrictive Spirometric Abnormality,” Scientific Reports 13, no. 1 (2023): 2988.

[33] R. Perez-Padilla, M. Montes de Oca, I. Thirion-Romero, et al., “Trajectories of Spirometric Patterns, Obstructive and PRISm, in a Population-Based Cohort in Latin America,” Int J Chron Obstruct Pulmon Dis 18 (2023): 1277-1285.

[34] S. Sin, E. J. Lee, S. Won, and W. J. Kim, “Longitudinal Mortality of Preserved Ratio Impaired Spirometry in a Middle-aged Asian Cohort,” BMC Pulm Med 23, no. 1 (2023): 155.

[35] C. Zhang, S. Wei, Y. Wang, et al., “Association Between Preserved Ratio Impaired Spirometry and Sleep Apnea in a Chinese Community,” Current Medical Research and Opinion 39, no. 4 (2023): 621-626.

[36] Y. J. Choi, M. J. Lee, M. K. Byun, et al., “Roles of Inflammatory Biomarkers in Exhaled Breath Condensates in Respiratory Clinical Fields,” Tuberc Respir Dis (Seoul) 87, no. 1 (2024): 65-79.

[37] D. He, M. Yan, Y. Zhou, et al., “Preserved Ratio Impaired Spirometry and COPD Accelerate Frailty Progression: Evidence from a Prospective Cohort Study,” Chest 165, no. 3 (2024): 573-582.

[38] Y. Im, H. Y. Park, J. Y. Lee, et al., “Impact of Preserved Ratio Impaired Spirometry on Coronary Artery Calcium Score Progression: A Longitudinal Cohort Study,” ERJ Open Res 10, no. 1 (2024).

[39] J. Lei, K. Huang, S. Wu, et al., “Heterogeneities and Impact Profiles of Early Chronic Obstructive Pulmonary Disease Status: Findings From the China Pulmonary Health Study,” Lancet Reg Health West Pac 45 (2024): 101021.

[40] C. C. Shu, M. K. Tsai, J. H. Lee, T. C. Su, and C. P. Wen, “Mortality Risk in Patients With Preserved Ratio Impaired Spirometry: Assessing the Role of Physical Activity,” Qjm (2024).

[41] Y. Zhang, J. Peng, L. Liu, et al., “Prevalence, Characteristics and Significant Predictors for Cardiovascular Disease of Patients With Preserved Ratio Impaired Spirometry: A 10-year Prospective Cohort Study in China,” Respiratory Medicine 222 (2024): 107523.

[42] S. Fortis, A. Comellas, V. Kim, et al., “Low FVC/TLC in Preserved Ratio Impaired Spirometry (PRISm) Is Associated With Features of and Progression to Obstructive Lung Disease,” Scientific Reports 10, no. 1 (2020): 5169.

[43] A. A. Diaz, W. Wang, J. L. Orejas, et al., “Suspected Bronchiectasis and Mortality in Adults with a History of Smoking Who Have Normal and Impaired Lung Function: A Cohort Study,” Annals of Internal Medicine 176, no. 10 (2023): 1340-1348.

[44] E. Pompe, M. Strand, E. M. van Rikxoort, et al., “Five-year Progression of Emphysema and Air Trapping at CT in Smokers With and Those Without Chronic Obstructive Pulmonary Disease: Results From the COPDGene Study,” Radiology 295, no. 1 (2020): 218-226.

[45] K. M. Leung, D. Curran-Everett, E. A. Regan, D. A. Lynch, and F. L. Jacobson, “Translation of Adapting Quantitative CT Data From Research to Local Clinical Practice: Validation Evaluation of Fully Automated Procedures to Provide Lung Volumes and Percent Emphysema,” J Med Imaging (Bellingham) 7, no. 2 (2020): 022404.

[46] J. Lu, H. Ge, L. Qi, et al., “Subtyping Preserved Ratio Impaired Spirometry (PRISm) by Using Quantitative HRCT Imaging Characteristics,” Respiratory Research 23, no. 1 (2022): 309.

[47] D. B. Phillips, M. D. James, S. G. Vincent, et al., “Physiological Characterization of Preserved Ratio Impaired Spirometry in the CanCOLD Study: Implications for Exertional Dyspnea and Exercise Intolerance,” American Journal of Respiratory and Critical Care Medicine (2024).

[48] S. M. Yoon, K. N. Jin, H. J. Lee, et al., “Acute Exacerbation and Longitudinal Lung Function Change of Preserved Ratio Impaired Spirometry,” Int J Chron Obstruct Pulmon Dis 19 (2024): 519-529.

[49] W. W. Labaki, A. Agusti, S. P. Bhatt, et al., “Leveraging Computed Tomography Imaging to Detect Chronic Obstructive Pulmonary Disease and Concomitant Chronic Diseases,” American Journal of Respiratory and Critical Care Medicine 210, no. 3 (2024): 281-287.

[50] E. L. O'Dowd, I. Tietzova, E. Bartlett, et al., “ERS/ESTS/ESTRO/ESR/ESTI/EFOMP Statement on Management of Incidental Findings From Low Dose CT Screening for Lung Cancer,” European Journal of Cardio-Thoracic Surgery 64, no. 4 (2023).

[51] D. H. Higbee, A. Lirio, F. Hamilton, et al., “Genome-wide Association Study of Preserved Ratio Impaired Spirometry (PRISm),” European Respiratory Journal 63, no. 1 (2024).

[52] M. J. Page, D. Moher, P. M. Bossuyt, et al., “PRISMA 2020 Explanation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews,” Bmj 372 (2021): n160.

[53] X. Wan, W. Wang, J. Liu, and T. Tong, “Estimating the Sample Mean and Standard Deviation From the Sample Size, Median, Range and/or Interquartile Range,” BMC Medical Research Methodology [Electronic Resource] 14 (2014): 135.

[54] G. A. Wells BS, D. O'Connell, J. Peterson, V. Welch, M. Losos, and P. Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed 2022/09/22, 2022. https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp.

[55] J. J. Barendregt, S. A. Doi, Y. Y. Lee, R. E. Norman, and T. Vos, “Meta-analysis of Prevalence,” Journal of Epidemiology and Community Health 67, no. 11 (2013): 974-978.

[56] M. Egger, G. Davey Smith, M. Schneider, and C. Minder, “Bias in Meta-analysis Detected by a Simple, Graphical Test,” Bmj 315, no. 7109 (1997): 629-634.

[57] S. Duval and R. Tweedie, “Trim and Fill: A Simple Funnel-plot-based Method of Testing and Adjusting for Publication Bias in Meta-analysis,” Biometrics 56, no. 2 (2000): 455-463.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.